2. Kumar Y, Yang J, Hu T, Chen L, Xu Z, Xu L,
et al. Massive interstitial copy-neutral loss-of-heterozygosity as evidence for cancer being a disease of the DNA-damage response. BMC Med Genomics 2015;8:42.
3. Yamazawa K, Ogata T, Ferguson-Smith AC. Uniparental disomy and human disease: an overview. Am J Med Genet C Semin Med Genet 2010;154C:329–334.
4. Nazarenko MS, Sleptcov AA, Lebedev IN, Skryabin NA, Markov AV, Golubenko MV,
et al. Genomic structural variations for cardiovascular and metabolic comorbidity. Sci Rep 2017;7:41268.
5. Muscogiuri G, Barrea L, Faggiano F, Maiorino MI, Parrillo M, Pugliese G,
et al. Obesity in Prader-Willi syndrome: physiopathological mechanisms, nutritional and pharmacological approaches. J Endocrinol Invest 2021;44:2057–2070.
6. Narasimhan ML, Khattab A. Genetics of congenital adrenal hyperplasia and genotype-phenotype correlation. Fertil Steril 2019;111:24–29.
7. Sivakumar S, San Lucas FA, Jakubek YA, Ozcan Z, Fowler J, Scheet P. Pan cancer patterns of allelic imbalance from chromosomal alterations in 33 tumor types. Genetics 2021;217:1–12.
8. Nichols CA, Gibson WJ, Brown MS, Kosmicki JA, Busanovich JP, Wei H,
et al. Loss of heterozygosity of essential genes represents a widespread class of potential cancer vulnerabilities. Nat Commun 2020;11:2517.
9. Ryland GL, Doyle MA, Goode D, Boyle SE, Choong DY, Rowley SM,
et al. Loss of heterozygosity: what is it good for? BMC Med Genomics 2015;8:45.
10. Melcher R, Hartmann E, Zopf W, Herterich S, Wilke P, Muller L,
et al. LOH and copy neutral LOH (cnLOH) act as alternative mechanism in sporadic colorectal cancers with chromosomal and microsatellite instability. Carcinogenesis 2011;32:636–642.
11. Jasek M, Gondek LP, Bejanyan N, Tiu R, Huh J, Theil KS,
et al.
TP53 mutations in myeloid malignancies are either homozygous or hemizygous due to copy number-neutral loss of heterozygosity or deletion of 17p. Leukemia 2010;24:216–219.
12. Lourenco N, Helias-Rodzewicz Z, Bachet JB, Brahimi-Adouane S, Jardin F, Tran van Nhieu J,
et al. Copy-neutral loss of heterozygosity and chromosome gains and losses are frequent in gastrointestinal stromal tumors. Mol Cancer 2014;13:246.
13. Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A,
et al. Comprehensive characterization of cancer driver genes and mutations. Cell 2018;173:371–385.
14. Favero F, Joshi T, Marquard AM, Birkbak NJ, Krzystanek M, Li Q,
et al. Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data. Ann Oncol 2015;26:64–70.
16. O'Hara AJ, Le Gallo M, Rudd ML, Bell DW. High-resolution copy number analysis of clear cell endometrial carcinoma. Cancer Genet 2020;240:5–14.
18. Sing T, Sander O, Beerenwinkel N, Lengauer T. ROCR: visualizing classifier performance in R. Bioinformatics 2005;21:3940–3941.
19. Salvatore S, Dagestad Rand K, Grytten I, Ferkingstad E, Domanska D, Holden L,
et al. Beware the Jaccard: the choice of similarity measure is important and non-trivial in genomic colocalisation analysis. Brief Bioinform 2020;21:1523–1530.
20. Yang L, Wang S, Lee JJ, Lee S, Lee E, Shinbrot E,
et al. An enhanced genetic model of colorectal cancer progression history. Genome Biol 2019;20:168.